ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the raised 2026 revenue and adjusted EPS ranges, while monitoring the disclosed margin contraction and higher cost lines (COGS ex-amortization and SG&A).
Market read
A same-day earnings beat plus upward guidance revision is a direct catalyst for estimate revisions and near-term trading in ZBH.
What to watch
Cash improved (FCF up), but adjusted operating profit fell year over year and SG&A rose 10.4%, implying cost pressure could reappear in subsequent quarters.
Background
Zacks reports Zimmer Biomet’s Q2 2026 results, including adjusted vs GAAP earnings, segment performance, margin metrics, cash flow, and an updated 2026 outlook.
Ticker impact
Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07 vs $2.01 consensus and raised 2026 guidance, lifting pre-market shares 1.4%.
Likely positive follow-through early as traders reprice 2026 estimates, with volatility around profitability given gross and operating margin declines.
The article discloses fresh, decision-relevant numbers: Q2 adjusted EPS and revenue beats, and an explicit upward revision to 2026 revenue and adjusted EPS ranges. It also flags margin contraction (adjusted gross margin down to 71.1% and operating margin down 210 bps), which can cap the rally or drive profit-taking.
Market effects
Medical device peers may see read-across demand and cost discipline signals, but the margin contraction highlights execution risk in orthopedics.
US and international sales both grew, suggesting broad-based demand rather than a single-region driver.
Constant-currency and organic growth improvements support a less FX-dependent outlook for the sector.
Counterpoint
The guidance raise may be driven by revenue growth while profitability deteriorates, so the stock could fade if investors focus on margin sustainability.
Key entities
- companyZimmer Biomet Holdings, Inc.
Reported Q2 2026 adjusted EPS and revenue beats, raised 2026 guidance, and showed margin contraction alongside improved cash flow.
